Diazepam: uses, dosing, side effects & brands

Diazepam is a benzodiazepine used to treat Alcohol Withdrawal Delirium, Muscle Spasticity, Status Epilepticus, Panic Disorder.

The FDA classifies diazepam as a benzodiazepine. Benzodiazepines boost the brain's main calming chemical, GABA, by binding to the GABA-A receptor and making its chloride channel open more often. This quiets nerve activity, producing sedation, reduced anxiety, muscle relaxation, and protection against seizures. If you are checking whether it is safe to combine with something else, the class is what matters — two drugs from the same class usually should not be stacked.

The label addresses alcohol directly. Because diazepam is a CNS depressant, the WARNINGS section advises patients against simultaneous ingestion of alcohol and other CNS-depressant drugs during therapy, and the Drug Interactions section states that concomitant use with alcohol is not recommended due to enhancement of the sedative effect. The boxed warning and abuse sections further note that mixing benzodiazepines with alcohol (and other CNS depressants) is associated with an increased frequency of serious adverse outcomes including respiratory depression, overdose, or death. This is additive CNS/sedative depression, not a disulfiram-like reaction. This is what diazepam's FDA label says; alcohol advice depends on your dose and health, so confirm with your pharmacist.

Yes, and it is in the BOXED warning. Continued use of diazepam may lead to clinically significant physical dependence, and abrupt discontinuation or rapid dosage reduction after continued use may precipitate acute withdrawal reactions that can be life-threatening (e.g., seizures). The label names acute withdrawal signs and symptoms including anxiety, insomnia, tremor, dizziness, blurred vision, restlessness, nausea/vomiting, tachycardia and hypertension, with more severe reactions such as catatonia, convulsions, delirium tremens, hallucinations, psychosis, seizures, and suicidality; it also describes a protracted withdrawal syndrome (anxiety, insomnia, cognitive impairment, paresthesia, tinnitus, motor symptoms) that can last from weeks to more than 12 months. To reduce this risk, the label directs the prescriber to use a gradual, patient-specific taper to discontinue or reduce the dose, and if withdrawal reactions develop, to pause the taper or return to the prior dose and then decrease more slowly. Risk is greater at higher doses and longer durations of use. Do not stop diazepam on your own — any change is a prescriber-managed decision.

The elimination half-life of diazepam is about 48 hours (up to 48 hours), but it varies strongly with age — roughly 20 hours at age 20 and rising by about 1 hour for each year of age — that is how long the body takes to clear half of a dose. This is the parent drug's half-life. Diazepam has an active metabolite, N-desmethyldiazepam (nordiazepam), whose half-life is much longer (up to 100 hours), so the drug's effects last well beyond the parent number. Clearance is also markedly slower in older adults and in liver disease — the half-life is 2 to 5 times longer in cirrhosis (individual cases over 500 hours) — so effective duration can be far longer. Half-life is not the same as how long a drug test can detect the drug, and it varies with age, kidney and liver function.

It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run diazepam against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.

We track 8 diazepam-containing products in the U.S.: Diazepam, Diastat, Diastat Acudial, Dizac, Libervant, Valium, Valrelease and Valtoco. They are the same active ingredient; they differ in form, manufacturer, price and FDA recall record.

Across the brands we track, diazepam is currently marketed as injectable, tablet, topical, film, capsule, extended release and spray/inhaler, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.

Yes. Our catalog lists 1 generic diazepam product alongside the brand versions. A generic has the same active ingredient and must meet the FDA's bioequivalence standard; it usually costs less. Ask your pharmacist which one your plan covers.

Alcohol: the FDA label says to avoid alcohol — see the alcohol section above for what it actually says. This is what the FDA label and our cited sources say — it is not a complete list. Your pharmacist can check your own combination.

Drowsiness, fatigue, muscle weakness, and ataxia — unsteadiness and loss of coordination. Those four are the ones the label names as most frequent. The practical consequence is that diazepam impairs driving and any task needing full alertness, and it raises fall risk in older adults. It also stacks with alcohol and with any other sedating drug, so the impairment is bigger than most people expect when they combine them.

Three separate dangers. First, combining diazepam with opioids can cause profound sedation, slowed or stopped breathing, coma, and death — this combination should be reserved for people with no adequate alternative, at the lowest dose and shortest duration possible. Second, diazepam carries risk of abuse, misuse, and addiction, which can lead to overdose or death; your prescriber should assess that risk before starting and keep checking. Third, continued use causes physical dependence, and stopping suddenly or cutting the dose fast after regular use can trigger acute withdrawal that is potentially life-threatening. All three apply even when the drug is taken exactly as prescribed.

The label lists specific contraindications — situations where diazepam is not to be used at all, not merely used cautiously. These are: known hypersensitivity to diazepam; infants under 6 months old; myasthenia gravis; severe respiratory insufficiency; severe liver insufficiency; sleep apnea syndrome; and acute narrow-angle glaucoma. People with open-angle glaucoma who are receiving appropriate treatment for it can use diazepam. Notice that sleep apnea and severe breathing problems are on this list because diazepam suppresses breathing — that is a 'do not use', not a 'be careful'.

You can go into acute withdrawal, and the label states this can be life-threatening — seizures are the reason. Withdrawal risk rises with longer use and higher daily doses. The label's instruction is to come off by gradual taper rather than stopping abruptly or dropping the dose quickly. This is not something to improvise: if you have been taking diazepam regularly, ask your prescriber for a taper schedule instead of stopping on your own, even if you have only been on it a short while.

Opioid painkillers plus diazepam is the specific combination in the boxed warning, and it can cause profound sedation, respiratory depression, coma, and death. Alcohol works on the same pathway and adds to the sedation and breathing suppression. So does any other CNS depressant — sleep medicines, muscle relaxants, sedating antihistamines. If you are prescribed both a benzodiazepine and an opioid, both prescribers need to know, and someone around you should know the signs of oversedation: unusual sleepiness, confusion, and slow or shallow breathing.

"In your system" means two different things. First, how long the drug keeps acting and then clears: this is tied to the elimination half-life. Diazepam's own half-life averages about 46 hours, but it is broken down into a long-lived active metabolite, N-desmethyldiazepam (nordiazepam), with a half-life of up to 100 hours (StatPearls). A drug is largely cleared after about 4-5 half-lives, so on the parent half-life alone that is roughly 9-10 days; because the active metabolite lingers up to ~100 hours each cycle, meaningful active drug can persist for about 2-3 weeks after regular use, which is why Valium is classed as long-acting. Second, how long a drug test can detect it, which is longer than the clinical effect and depends on the test type (urine, blood, saliva, or hair). The figures below are approximate laboratory ranges, not guarantees; only a clinician or testing lab can interpret a specific result.

Urine is the most common test. For benzodiazepines, published clinical ranges run from about 1 day up to roughly 6 weeks, with the long end reflecting heavy or chronic use of a long-acting agent like diazepam and its slow-clearing metabolite nordiazepam (MedCentral, Interpreting Benzodiazepine Urine Drug Screen Results). A single therapeutic dose usually falls near the short end; sustained daily use extends it toward weeks. The exact window depends on dose, how long and how often it was used, individual metabolism, hydration, and the specific assay and its cutoff. One honest, useful caveat: standard benzodiazepine immunoassay screens are optimized for diazepam-type metabolites and detect Valium well, but the same screens can MISS other benzodiazepines such as clonazepam and lorazepam, which have limited cross-reactivity with traditional immunoassays and often require confirmatory GC-MS or LC-MS/MS testing. These are approximate ranges, not guarantees.

Blood windows are the shortest: benzodiazepines are typically detectable in blood for about 12-24 hours after the last dose, though a long-acting drug like diazepam and its metabolite can be measurable somewhat longer. In saliva (oral fluid), a study of patients after high and repeated intake found diazepam detectable up to about 7 days and its metabolite N-desmethyldiazepam up to about 9 days (PubMed, Detection Times of Diazepam, Clonazepam, and Alprazolam in Oral Fluid); a single dose clears much faster. Hair testing has the longest window: because scalp hair grows roughly 1 cm per month, a standard hair test can reflect exposure over about the prior 90 days, though it is less reliable for very recent use and detects long-acting benzodiazepines like diazepam more readily than short-acting ones. All of these are approximate ranges from laboratory references, not guarantees.

Several factors shift the numbers. Dose and frequency matter most: a single dose clears far faster than chronic daily use, which lets the long-lived active metabolite nordiazepam accumulate and extend detection. Metabolism plays a large role, including age (older adults clear diazepam more slowly), and liver or kidney function, since impaired clearance prolongs it. Body composition matters because diazepam is fat-soluble and can be stored in and slowly released from body fat. Hydration and urine concentration affect urine screen results, and the specific test's cutoff threshold changes what counts as a positive. Because of all this variability, these are approximate ranges from laboratory references, not guarantees, and only a clinician or testing lab can interpret a specific result. Do not stop or change a prescribed medication without talking to the prescriber who ordered it.